BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov 2018;17:353-77. [PMID: 29545548 DOI: 10.1038/nrd.2018.21] [Cited by in Crossref: 373] [Cited by in F6Publishing: 334] [Article Influence: 93.3] [Reference Citation Analysis]
Number Citing Articles
1 Fleming CL, Grøtli M, Andréasson J. On‐Command Regulation of Kinase Activity using Photonic Stimuli. ChemPhotoChem 2019;3:318-26. [DOI: 10.1002/cptc.201800253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
2 Imoto H, Okada M. Signal-dependent regulation of early-response genes and cell cycle: a quantitative view. Current Opinion in Systems Biology 2019;15:100-8. [DOI: 10.1016/j.coisb.2019.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Stoppelman JP, Ng TT, Nerenberg PS, Wang LP. Development and Validation of AMBER-FB15-Compatible Force Field Parameters for Phosphorylated Amino Acids. J Phys Chem B 2021;125:11927-42. [PMID: 34668708 DOI: 10.1021/acs.jpcb.1c07547] [Reference Citation Analysis]
4 Krajcovicova S, Jorda R, Hendrychova D, Krystof V, Soural M. Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC). Chem Commun (Camb) 2019;55:929-32. [PMID: 30601480 DOI: 10.1039/c8cc08716d] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Li J, Van Valkenburgh J, Hong X, Conti PS, Zhang X, Chen K. Small molecules as theranostic agents in cancer immunology. Theranostics 2019;9:7849-71. [PMID: 31695804 DOI: 10.7150/thno.37218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
6 Manschwetus JT, Bendzunas GN, Limaye AJ, Knape MJ, Herberg FW, Kennedy EJ. A Stapled Peptide Mimic of the Pseudosubstrate Inhibitor PKI Inhibits Protein Kinase A. Molecules 2019;24:E1567. [PMID: 31009996 DOI: 10.3390/molecules24081567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Chen X, Hu Z, Zhou L, Zhang F, Wan J, Wang H. Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy. Nanoscale Horiz 2021;6:33-42. [DOI: 10.1039/d0nh00469c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Drug Discov Today Technol 2019;31:15-27. [PMID: 31200855 DOI: 10.1016/j.ddtec.2019.01.002] [Cited by in Crossref: 192] [Cited by in F6Publishing: 174] [Article Influence: 64.0] [Reference Citation Analysis]
9 Guo H, He Y, Chen P, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, Zhou C. Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation? J Thorac Dis 2020;12:6070-89. [PMID: 33209440 DOI: 10.21037/jtd-20-1689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen X, Liu H, Xie W, Yang Y, Wang Y, Fan Y, Hua Y, Zhu L, Zhao J, Lu T, Chen Y, Zhang Y. Investigation of Crystal Structures in Structure-Based Virtual Screening for Protein Kinase Inhibitors. J Chem Inf Model 2019;59:5244-62. [PMID: 31689093 DOI: 10.1021/acs.jcim.9b00684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Wang H, Gao Y, Wang J, Cheng M. Computational Strategy Revealing the Structural Determinant of Ligand Selectivity towards Highly Similar Protein Targets. Curr Drug Targets 2020;21:76-88. [PMID: 31556854 DOI: 10.2174/1389450120666190926113524] [Reference Citation Analysis]
12 Xie Z, Yang X, Duan Y, Han J, Liao C. Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. J Med Chem 2021;64:1283-345. [PMID: 33481605 DOI: 10.1021/acs.jmedchem.0c01511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
13 Wang Z, Cai J, Cheng J, Yang W, Zhu Y, Li H, Lu T, Chen Y, Lu S. FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. J Med Chem 2021;64:2878-900. [PMID: 33719439 DOI: 10.1021/acs.jmedchem.0c01851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Li L, Zhu M, Wu W, Qin B, Gu J, Tu Y, Chen J, Liu D, Shi Y, Liu X, Sang A, Ding D. Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD. J Cell Physiol 2020;235:1259-73. [DOI: 10.1002/jcp.29041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Fleming CL, Sandoz PA, Inghardt T, Önfelt B, Grøtli M, Andréasson J. A Fluorescent Kinase Inhibitor that Exhibits Diagnostic Changes in Emission upon Binding. Angew Chem Int Ed Engl 2019;58:15000-4. [PMID: 31411364 DOI: 10.1002/anie.201909536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Shrivastava S, Nagi R, Sharma S, Rasul Sanadi SA, Dafallah ET, Ragit A. Molecular targeted therapy: novel therapeutic approach for head and neck cancer. Therapeutic Delivery 2020;11:637-51. [DOI: 10.4155/tde-2020-0028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Deng W, Chen X, Jiang K, Song X, Huang M, Tu ZC, Zhang Z, Lin X, Ortega R, Patterson AV, Smaill JB, Ding K, Chen S, Chen Y, Lu X. Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Med Chem Lett 2021;12:647-52. [PMID: 33859803 DOI: 10.1021/acsmedchemlett.1c00052] [Reference Citation Analysis]
18 Zhao Q, Ren C, Liu L, Chen J, Shao Y, Sun N, Sun R, Kong Y, Ding X, Zhang X, Xu Y, Yang B, Yin Q, Yang X, Jiang B. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase. J Med Chem 2019;62:9281-98. [DOI: 10.1021/acs.jmedchem.9b01264] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
19 Mondal D, Amin SA, Moinul M, Das K, Jha T, Gayen S. How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors. Bioorg Med Chem 2022;53:116534. [PMID: 34864496 DOI: 10.1016/j.bmc.2021.116534] [Reference Citation Analysis]
20 Li Q, Sun M, Wang M, Feng M, Yang F, Li L, Zhao J, Chang C, Dong H, Xie T, Chen J. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci 2021;112:1695-706. [PMID: 33605517 DOI: 10.1111/cas.14861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
21 Ung PM, DeVita RJ, Schlessinger A. Encounter and React: Computer-Guided Design of Covalent Inhibitors. Cell Chem Biol 2019;26:6-8. [PMID: 30658111 DOI: 10.1016/j.chembiol.2018.12.009] [Reference Citation Analysis]
22 Guo J, Collins S, Miller WT, Rizzo RC. Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring. Biochemistry 2018;57:4934-51. [PMID: 29975516 DOI: 10.1021/acs.biochem.8b00524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Massalska M, Maslinski W, Ciechomska M. Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. Cells 2020;9:E1876. [PMID: 32796683 DOI: 10.3390/cells9081876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
24 Yuan K, Wang X, Dong H, Min W, Hao H, Yang P. Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B 2021;11:30-54. [PMID: 33532179 DOI: 10.1016/j.apsb.2020.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
25 Salem O, Hansen CG. The Hippo Pathway in Prostate Cancer. Cells 2019;8:E370. [PMID: 31018586 DOI: 10.3390/cells8040370] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
26 Chen AY, Adamek RN, Dick BL, Credille CV, Morrison CN, Cohen SM. Targeting Metalloenzymes for Therapeutic Intervention. Chem Rev 2019;119:1323-455. [PMID: 30192523 DOI: 10.1021/acs.chemrev.8b00201] [Cited by in Crossref: 77] [Cited by in F6Publishing: 57] [Article Influence: 19.3] [Reference Citation Analysis]
27 Thomas MG, De Rycker M, Ajakane M, Albrecht S, Álvarez-Pedraglio AI, Boesche M, Brand S, Campbell L, Cantizani-Perez J, Cleghorn LAT, Copley RCB, Crouch SD, Daugan A, Drewes G, Ferrer S, Ghidelli-Disse S, Gonzalez S, Gresham SL, Hill AP, Hindley SJ, Lowe RM, MacKenzie CJ, MacLean L, Manthri S, Martin F, Miguel-Siles J, Nguyen VL, Norval S, Osuna-Cabello M, Woodland A, Patterson S, Pena I, Quesada-Campos MT, Reid IH, Revill C, Riley J, Ruiz-Gomez JR, Shishikura Y, Simeons FRC, Smith A, Smith VC, Spinks D, Stojanovski L, Thomas J, Thompson S, Underwood T, Gray DW, Fiandor JM, Gilbert IH, Wyatt PG, Read KD, Miles TJ. Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem 2019;62:1180-202. [PMID: 30570265 DOI: 10.1021/acs.jmedchem.8b01218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
28 Heger-Stevic J, Zimmermann P, Lecoq L, Böttcher B, Nassal M. Hepatitis B virus core protein phosphorylation: Identification of the SRPK1 target sites and impact of their occupancy on RNA binding and capsid structure. PLoS Pathog 2018;14:e1007488. [PMID: 30566530 DOI: 10.1371/journal.ppat.1007488] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
29 Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist 2020;13:513-32. [PMID: 32110062 DOI: 10.2147/IDR.S233137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ma S, Strømgaard K, Clemmensen LS. Site-Specific Phosphorylation of PDZ Domains. Methods Mol Biol 2020;2133:235-61. [PMID: 32144671 DOI: 10.1007/978-1-0716-0434-2_12] [Reference Citation Analysis]
31 Zhang X, Zhang Z, Cao M, Liu B, Mori M, Luoh SW, Bergan R, Liu Y, Liu Y. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer. Clin Breast Cancer 2020;20:291-299.e3. [PMID: 32482525 DOI: 10.1016/j.clbc.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Castelli G, Pelosi E, Testa U. Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers (Basel) 2019;11:E260. [PMID: 30813354 DOI: 10.3390/cancers11020260] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
33 Enzler F, Tschaikner P, Schneider R, Stefan E. KinCon: Cell-based recording of full-length kinase conformations. IUBMB Life 2020;72:1168-74. [PMID: 32027084 DOI: 10.1002/iub.2241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Carpentier G, Berndt S, Ferratge S, Rasband W, Cuendet M, Uzan G, Albanese P. Angiogenesis Analyzer for ImageJ - A comparative morphometric analysis of "Endothelial Tube Formation Assay" and "Fibrin Bead Assay". Sci Rep 2020;10:11568. [PMID: 32665552 DOI: 10.1038/s41598-020-67289-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
35 Bajorath J. Minimal screening requirements for identifying highly promiscuous kinase inhibitors. Future Med Chem 2021;13:1083-5. [PMID: 33998280 DOI: 10.4155/fmc-2021-0077] [Reference Citation Analysis]
36 Rahman R, Ung PM, Schlessinger A. KinaMetrix: a web resource to investigate kinase conformations and inhibitor space. Nucleic Acids Res 2019;47:D361-6. [PMID: 30321373 DOI: 10.1093/nar/gky916] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
37 Katan M, Cockcroft S. Phospholipase C families: Common themes and versatility in physiology and pathology. Prog Lipid Res 2020;80:101065. [PMID: 32966869 DOI: 10.1016/j.plipres.2020.101065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Kuleshov MV, Xie Z, London ABK, Yang J, Evangelista JE, Lachmann A, Shu I, Torre D, Ma'ayan A. KEA3: improved kinase enrichment analysis via data integration. Nucleic Acids Res 2021;49:W304-16. [PMID: 34019655 DOI: 10.1093/nar/gkab359] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Bertolotti A. The split protein phosphatase system. Biochem J 2018;475:3707-23. [PMID: 30523060 DOI: 10.1042/BCJ20170726] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
40 Fraser NJ, Howie J, Wypijewski KJ, Fuller W. Therapeutic targeting of protein S-acylation for the treatment of disease. Biochemical Society Transactions 2020;48:281-90. [DOI: 10.1042/bst20190707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
41 Ball B, Abdel-Wahab O. Activating p53 and Inhibiting Superenhancers to Cure Leukemia. Trends Pharmacol Sci 2018;39:1002-4. [PMID: 30454768 DOI: 10.1016/j.tips.2018.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Li X, Huang R, Li M, Zhu Z, Chen Z, Cui L, Luo H, Luo L. Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor. Cancer Cell Int 2020;20:561. [PMID: 33292235 DOI: 10.1186/s12935-020-01658-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Lu H, Iuliano JN, Tonge PJ. Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics. Curr Opin Chem Biol 2018;44:101-9. [PMID: 29986213 DOI: 10.1016/j.cbpa.2018.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
44 Korovesis D, Beard HA, Mérillat C, Verhelst SHL. Probes for Photoaffinity Labelling of Kinases. Chembiochem 2021;22:2206-18. [PMID: 33544409 DOI: 10.1002/cbic.202000874] [Reference Citation Analysis]
45 Ong LL, Vasta JD, Monereau L, Locke G, Ribeiro H, Pattoli MA, Skala S, Burke JR, Watterson SH, Tino JA, Meisenheimer PL, Arey B, Lippy J, Zhang L, Robers MB, Tebben A, Chaudhry C. A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton's Tyrosine Kinase. SLAS Discov 2020;25:176-85. [PMID: 31709883 DOI: 10.1177/2472555219884881] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology 2020;94:481-94. [PMID: 32102975 DOI: 10.1212/WNL.0000000000009107] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 18.5] [Reference Citation Analysis]
47 Lorenz R, Wu J, Herberg FW, Taylor SS, Engh RA. Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics. Biochemistry 2021. [PMID: 34370450 DOI: 10.1021/acs.biochem.1c00359] [Reference Citation Analysis]
48 O'Byrne SN, Eduful BJ, Willson TM, Drewry DH. Concise, gram-scale synthesis of furo[2,3-b]pyridines with functional handles for chemoselective cross-coupling. Tetrahedron Lett 2020;61:152353. [PMID: 33012852 DOI: 10.1016/j.tetlet.2020.152353] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Rocha-Roa C, Molina D, Cardona N. A Perspective on Thiazolidinone Scaffold Development as a New Therapeutic Strategy for Toxoplasmosis. Front Cell Infect Microbiol 2018;8:360. [PMID: 30386743 DOI: 10.3389/fcimb.2018.00360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770-803. [PMID: 32162523 DOI: 10.1021/acs.jnatprod.9b01285] [Cited by in Crossref: 622] [Cited by in F6Publishing: 560] [Article Influence: 311.0] [Reference Citation Analysis]
51 Praphanwittaya P, Saokham P, Jansook P, Loftsson T. Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization. Journal of Drug Delivery Science and Technology 2020;55:101462. [DOI: 10.1016/j.jddst.2019.101462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
52 Arrington J, Xue L, Wang WH, Geahlen RL, Tao WA. Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments. J Proteome Res 2019;18:1679-90. [PMID: 30869898 DOI: 10.1021/acs.jproteome.8b00942] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Hu H, Laufkötter O, Miljković F, Bajorath J. Systematic comparison of competitive and allosteric kinase inhibitors reveals common structural characteristics. Eur J Med Chem 2021;214:113206. [PMID: 33540355 DOI: 10.1016/j.ejmech.2021.113206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Backus KM, Cao J, Maddox SM. Opportunities and challenges for the development of covalent chemical immunomodulators. Bioorg Med Chem 2019;27:3421-39. [PMID: 31204229 DOI: 10.1016/j.bmc.2019.05.050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
55 Duan R, Xu Y, Zeng X, Xu J, Liang L, Zhang Z, Wang Z, Jiang X, Xing B, Liu B, All A, Li X, Lee LP, Liu X. Uncovering the Metabolic Origin of Aspartate for Tumor Growth Using an Integrated Molecular Deactivator. Nano Lett 2021;21:778-84. [PMID: 33301328 DOI: 10.1021/acs.nanolett.0c04520] [Reference Citation Analysis]
56 Hoch NC, Polo LM. ADP-ribosylation: from molecular mechanisms to human disease. Genet Mol Biol 2019;43:e20190075. [PMID: 31930280 DOI: 10.1590/1678-4685-GMB-2019-0075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
57 Unzue A, Jessen-Trefzer C, Spiliotopoulos D, Gaudio E, Tarantelli C, Dong J, Zhao H, Pachmayr J, Zahler S, Bernasconi E, Sartori G, Cascione L, Bertoni F, Śledź P, Caflisch A, Nevado C. Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors. RSC Med Chem 2020;11:665-75. [PMID: 33479666 DOI: 10.1039/d0md00049c] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Carmell N, Rominiyi O, Myers KN, McGarrity-Cottrell C, Vanderlinden A, Lad N, Perroux-David E, El-Khamisy SF, Fernando M, Finegan KG, Brown S, Collis SJ. Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma. Cancers (Basel) 2021;13:944. [PMID: 33668183 DOI: 10.3390/cancers13050944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res 2019;142:151-68. [PMID: 30794926 DOI: 10.1016/j.phrs.2019.01.039] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 24.7] [Reference Citation Analysis]
60 Zhu Y, Alqahtani S, Hu X. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors. Molecules 2021;26:1776. [PMID: 33810025 DOI: 10.3390/molecules26061776] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Chaudhry C, Tebben A, Tokarski JS, Borzilleri R, Pitts WJ, Lippy J, Zhang L. An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. Drug Discov Today 2021;26:1115-25. [PMID: 33497831 DOI: 10.1016/j.drudis.2021.01.018] [Reference Citation Analysis]
62 Xi M, Chen Y, Yang H, Xu H, Du K, Wu C, Xu Y, Deng L, Luo X, Yu L, Wu Y, Gao X, Cai T, Chen B, Shen R, Sun H. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation. Eur J Med Chem 2019;174:159-80. [PMID: 31035238 DOI: 10.1016/j.ejmech.2019.04.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
63 Cheng W, Ma J, Xiang L, Sun Y, Huang W, Zhang Z, Kong D, Li J. Zr4+-mediated hybrid chain reaction and its application for highly sensitive electrochemical detection of protein kinase A. Bioelectrochemistry 2021;140:107796. [PMID: 33744680 DOI: 10.1016/j.bioelechem.2021.107796] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 [DOI: 10.1101/2021.02.12.430923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Long MJ, Liu X, Aye Y. Genie in a bottle: controlled release helps tame natural polypharmacology? Curr Opin Chem Biol 2019;51:48-56. [PMID: 30913473 DOI: 10.1016/j.cbpa.2019.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
66 Balmaña M, Diniz F, Feijão T, Barrias CC, Mereiter S, Reis CA. Analysis of the Effect of Increased α2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib. Int J Mol Sci 2020;21:E722. [PMID: 31979110 DOI: 10.3390/ijms21030722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Fathi NN, Mohammad DK, Görgens A, Andaloussi SE, Zain R, Nore BF, Smith CIE. Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. Biochem Biophys Res Commun 2018;504:749-52. [PMID: 30217447 DOI: 10.1016/j.bbrc.2018.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
68 Shen Z, Yan YH, Yang S, Zhu S, Yuan Y, Qiu Z, Jia H, Wang R, Li GB, Li H. ProfKin: A comprehensive web server for structure-based kinase profiling. Eur J Med Chem 2021;225:113772. [PMID: 34411891 DOI: 10.1016/j.ejmech.2021.113772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Arora N, Raj A, Anjum F, Kaur R, Rawat SS, Kumar R, Tripathi S, Singh G, Prasad A. Unveiling Taenia solium kinome profile and its potential for new therapeutic targets. Expert Review of Proteomics 2020;17:85-94. [DOI: 10.1080/14789450.2020.1719835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Asquith CRM, Tizzard GJ, Bennett JM, Wells CI, Elkins JM, Willson TM, Poso A, Laitinen T. Targeting the Water Network in Cyclin G‐Associated Kinase (GAK) with 4‐Anilino‐quin(az)oline Inhibitors. ChemMedChem 2020;15:1200-15. [DOI: 10.1002/cmdc.202000150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Rimkus CM, Schoeps VA, Boaventura M, Godoy LF, Apostolos-Pereira SL, Calich AL, Callegaro D, Lucato LT, Rovira A, Sastre-Garriga J, Leite CDC. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Mult Scler Relat Disord 2021;55:103146. [PMID: 34332456 DOI: 10.1016/j.msard.2021.103146] [Reference Citation Analysis]
72 Wells CI, Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Ingold MR, Pickett JE, Drewry DH, Pugh KM, Schwinn MK, Hwang BB, Zegzouti H, Huber KVM, Cong M, Meisenheimer PL, Willson TM, Robers MB. Quantifying CDK inhibitor selectivity in live cells. Nat Commun 2020;11:2743. [PMID: 32488087 DOI: 10.1038/s41467-020-16559-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
73 Song Z, Wang M, Ge Y, Chen XP, Xu Z, Sun Y, Xiong XF. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. Acta Pharm Sin B 2021;11:13-29. [PMID: 33532178 DOI: 10.1016/j.apsb.2020.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
74 Kuhlen M, Klusmann JH, Hoell JI. Molecular Approaches to Treating Pediatric Leukemias. Front Pediatr 2019;7:368. [PMID: 31555628 DOI: 10.3389/fped.2019.00368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
75 Jin W. Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications. Cancers (Basel) 2020;12:E1339. [PMID: 32456226 DOI: 10.3390/cancers12051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
76 Mandal R, Becker S, Strebhardt K. Targeting CDK9 for Anti-Cancer Therapeutics. Cancers (Basel) 2021;13:2181. [PMID: 34062779 DOI: 10.3390/cancers13092181] [Reference Citation Analysis]
77 Krämer A, Kurz CG, Berger BT, Celik IE, Tjaden A, Greco FA, Knapp S, Hanke T. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor. Eur J Med Chem 2020;208:112770. [PMID: 32883634 DOI: 10.1016/j.ejmech.2020.112770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Gehringer M, Laufer SA. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J Med Chem 2019;62:5673-724. [PMID: 30565923 DOI: 10.1021/acs.jmedchem.8b01153] [Cited by in Crossref: 167] [Cited by in F6Publishing: 135] [Article Influence: 55.7] [Reference Citation Analysis]
79 [DOI: 10.1101/2019.12.22.886523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Shan W, Yuan J, Hu Z, Jiang J, Wang Y, Loo N, Fan L, Tang Z, Zhang T, Xu M, Pan Y, Lu J, Long M, Tanyi JL, Montone KT, Fan Y, Hu X, Zhang Y, Zhang L. Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment. Cell Rep 2020;32:107884. [PMID: 32668240 DOI: 10.1016/j.celrep.2020.107884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
81 Wu MD, Moslehi JJ, Lindner JR. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arterioscler Thromb Vasc Biol 2021;41:3-10. [PMID: 33275447 DOI: 10.1161/ATVBAHA.120.314694] [Reference Citation Analysis]
82 Shevchenko E, Poso A, Pantsar T. The autoinhibited state of MKK4: Phosphorylation, putative dimerization and R134W mutant studied by molecular dynamics simulations. Comput Struct Biotechnol J 2020;18:2687-98. [PMID: 33101607 DOI: 10.1016/j.csbj.2020.09.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Cao Y, Zhou H, Chen X, Li Y, Hu J, Zhou G, Wang L. Recent insight into the role of RING-finger E3 ligases in glioma. Biochem Soc Trans 2021;49:519-29. [PMID: 33544148 DOI: 10.1042/BST20201060] [Reference Citation Analysis]
84 Peng Y, Wu Z, Yang H, Cai Y, Liu G, Li W, Tang Y. Insights into mechanisms and severity of drug-induced liver injury via computational systems toxicology approach. Toxicology Letters 2019;312:22-33. [DOI: 10.1016/j.toxlet.2019.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
85 Grant P, Kumar J, Kar S, Overduin M. Effects of Specific Inhibitors for CaMK1D on a Primary Neuron Model for Alzheimer’s Disease. Molecules 2021;26:7669. [DOI: 10.3390/molecules26247669] [Reference Citation Analysis]
86 Foulkes DM, Byrne DP, Yeung W, Shrestha S, Bailey FP, Ferries S, Eyers CE, Keeshan K, Wells C, Drewry DH, Zuercher WJ, Kannan N, Eyers PA. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Sci Signal 2018;11:eaat7951. [PMID: 30254057 DOI: 10.1126/scisignal.aat7951] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
87 Němec V, Maier L, Berger BT, Chaikuad A, Drápela S, Souček K, Knapp S, Paruch K. Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. Eur J Med Chem 2021;215:113299. [PMID: 33636538 DOI: 10.1016/j.ejmech.2021.113299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Wongtrakul J, Thongtan T, Pannengpetch S, Wikan N, Kantamala D, Kumrapich B, Suwan W, Smith DR. Phosphoproteomic analysis of dengue virus infected U937 cells and identification of pyruvate kinase M2 as a differentially phosphorylated phosphoprotein. Sci Rep 2020;10:14493. [PMID: 32879337 DOI: 10.1038/s41598-020-71407-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Rajan SS, Amin AD, Li L, Rolland DC, Li H, Kwon D, Kweh MF, Arumov A, Roberts ER, Yan A, Basrur V, Elenitoba-Johnson KSJ, Chen XS, Puvvada SD, Lussier YA, Bilbao D, Lim MS, Schatz JH. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. Oncogene 2020;39:2103-17. [PMID: 31804622 DOI: 10.1038/s41388-019-1136-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Vaidya SD, Toenjes ST, Yamamoto N, Maddox SM, Gustafson JL. Catalytic Atroposelective Synthesis of N-Aryl Quinoid Compounds. J Am Chem Soc 2020;142:2198-203. [PMID: 31944689 DOI: 10.1021/jacs.9b12994] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
91 Panicker RC, Chattopadhaya S, Coyne AG, Srinivasan R. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. Adv Exp Med Biol 2019;1163:253-78. [PMID: 31707707 DOI: 10.1007/978-981-13-8719-7_11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
92 Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. Clin Cancer Res 2021;27:4301-10. [PMID: 33664059 DOI: 10.1158/1078-0432.CCR-21-0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Wagner TR, Rothbauer U. Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell. Biomolecules 2020;10:E1701. [PMID: 33371447 DOI: 10.3390/biom10121701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Salguero AL, Chen M, Balana AT, Chu N, Jiang H, Palanski BA, Bae H, Wright KM, Nathan S, Zhu H, Gabelli SB, Pratt MR, Cole PA. Multifaceted Regulation of Akt by Diverse C-Terminal Post-translational Modifications. ACS Chem Biol 2021. [PMID: 34941261 DOI: 10.1021/acschembio.1c00632] [Reference Citation Analysis]
95 Nováček V, McGauran G, Matallanas D, Vallejo Blanco A, Conca P, Muñoz E, Costabello L, Kanakaraj K, Nawaz Z, Walsh B, Mohamed SK, Vandenbussche PY, Ryan CJ, Kolch W, Fey D. Accurate prediction of kinase-substrate networks using knowledge graphs. PLoS Comput Biol 2020;16:e1007578. [PMID: 33270624 DOI: 10.1371/journal.pcbi.1007578] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Abbas HS, Abd El-karim SS. Design, synthesis and anticervical cancer activity of new benzofuran–pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. Bioorganic Chemistry 2019;89:103035. [DOI: 10.1016/j.bioorg.2019.103035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
97 do Amaral DN, Lategahn J, Fokoue HH, da Silva EMB, Sant'Anna CMR, Rauh D, Barreiro EJ, Laufer S, Lima LM. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Sci Rep 2019;9:14. [PMID: 30626888 DOI: 10.1038/s41598-018-36846-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
98 Liu B, Yuan X, Xu B, Zhang H, Li R, Wang X, Ge Z, Li R. Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors. European Journal of Medicinal Chemistry 2019;170:1-15. [DOI: 10.1016/j.ejmech.2019.03.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
99 Islam S, Wang S, Bowden N, Martin J, Head R. Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target. Br J Clin Pharmacol 2021. [PMID: 34192364 DOI: 10.1111/bcp.14964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Andreev S, Pantsar T, Tesch R, Kahlke N, El-Gokha A, Ansideri F, Grätz L, Romasco J, Sita G, Geibel C, Lämmerhofer M, Tarozzi A, Knapp S, Laufer SA, Koch P. Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors. J Med Chem 2021. [PMID: 34213342 DOI: 10.1021/acs.jmedchem.0c02146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Jiang Y, Rakesh K, Alharbi NS, Vivek H, Manukumar H, Mohammed Y, Qin H. Radical scavenging and anti-inflammatory activities of (hetero)arylethenesulfonyl fluorides: Synthesis and structure-activity relationship (SAR) and QSAR studies. Bioorganic Chemistry 2019;89:103015. [DOI: 10.1016/j.bioorg.2019.103015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
102 Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao Y, Natarajan V, Lakshmikanthan S, Chrzanowska-Wodnicka M, Dudek AZ, Claesson-Welsh L, Kitajewski JK, Wary KK, Malik AB, Mehta D. Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling. Cell Rep 2019;29:3472-3487.e4. [PMID: 31825830 DOI: 10.1016/j.celrep.2019.11.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
103 Toenjes ST, Garcia V, Maddox SM, Dawson GA, Ortiz MA, Piedrafita FJ, Gustafson JL. Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. ACS Chem Biol 2019;14:1930-9. [PMID: 31424197 DOI: 10.1021/acschembio.9b00407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
104 Rao S, Du G, Hafner M, Subramanian K, Sorger PK, Gray NS. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem 2019;294:8664-73. [PMID: 30858179 DOI: 10.1074/jbc.RA118.006805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
105 Wang L, Zhang Q, You Q. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer. Med Res Rev 2021. [PMID: 33846988 DOI: 10.1002/med.21807] [Reference Citation Analysis]
106 Kolarski D, Sugiyama A, Breton G, Rakers C, Ono D, Schulte A, Tama F, Itami K, Szymanski W, Hirota T, Feringa BL. Controlling the Circadian Clock with High Temporal Resolution through Photodosing. J Am Chem Soc 2019;141:15784-91. [PMID: 31509406 DOI: 10.1021/jacs.9b05445] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
107 Lindberg MF, Meijer L. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. Int J Mol Sci 2021;22:6047. [PMID: 34205123 DOI: 10.3390/ijms22116047] [Reference Citation Analysis]
108 Huang X, Xie Z, Liao C. Developing polo-like kinase 1 inhibitors. Future Medicinal Chemistry 2020;12:869-71. [DOI: 10.4155/fmc-2020-0055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Williams CAC, Soufi A, Pollard SM. Post-translational modification of SOX family proteins: Key biochemical targets in cancer? Semin Cancer Biol 2020;67:30-8. [PMID: 31539559 DOI: 10.1016/j.semcancer.2019.09.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
110 Zhao Z, Bourne PE. Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. J Chem Theory Comput 2020;16:3152-61. [PMID: 32283024 DOI: 10.1021/acs.jctc.9b01134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Wu B, Zhang L, Yu Y, Lu T, Zhang Y, Zhu W, Song Q, Lv C, Guo J, Tian Y, Deng N. miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis. Cell Death Dis 2020;11:345. [PMID: 32393810 DOI: 10.1038/s41419-020-2501-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
112 Tabtimmai L, Srisook P, Kuaprasert B, Thumanu K, Choowongkomon K. FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells. J Biophotonics 2020;13. [DOI: 10.1002/jbio.201960012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Recondo G, Mahjoubi L, Maillard A, Loriot Y, Bigot L, Facchinetti F, Bahleda R, Gazzah A, Hollebecque A, Mezquita L, Planchard D, Naltet C, Lavaud P, Lacroix L, Richon C, Lovergne AA, De Baere T, Tselikas L, Deas O, Nicotra C, Ngo-Camus M, Frias RL, Solary E, Angevin E, Eggermont A, Olaussen KA, Vassal G, Michiels S, Andre F, Scoazec JY, Massard C, Soria JC, Besse B, Friboulet L. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. NPJ Precis Oncol 2020;4:27. [PMID: 32964129 DOI: 10.1038/s41698-020-00130-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Faraj Pour Mojdehi M, Ganjali Koli M, Dolatkhah Ouch Bolagh M, Ghane Gardeh M, Hashemianzadeh SM. A detailed computational study on binding of kinase inhibitors into β-cyclodextrin: inclusion complex formation. Mol Syst Des Eng 2021;6:80-92. [DOI: 10.1039/d0me00140f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
115 Tan L, Gray NS. When Kinases Meet PROTACs: When Kinases Meet PROTACs . Chin J Chem 2018;36:971-7. [DOI: 10.1002/cjoc.201800293] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
116 Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, Sausville EL, Lukow DA, Liu L, Chait AR, Galluzzo ZC, Tucker C, Sheltzer JM. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 2019;11:eaaw8412. [PMID: 31511426 DOI: 10.1126/scitranslmed.aaw8412] [Cited by in Crossref: 173] [Cited by in F6Publishing: 142] [Article Influence: 86.5] [Reference Citation Analysis]
117 Tsai CC, Yue Z, Shen J. How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase. J Am Chem Soc 2019;141:15092-101. [PMID: 31476863 DOI: 10.1021/jacs.9b06064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
118 Hijazi M, Smith R, Rajeeve V, Bessant C, Cutillas PR. Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring. Nat Biotechnol 2020;38:493-502. [PMID: 31959955 DOI: 10.1038/s41587-019-0391-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
119 Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discov 2021;11:126-41. [PMID: 33004339 DOI: 10.1158/2159-8290.CD-20-0571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
120 Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. J Med Chem 2020;63:1624-41. [PMID: 31935084 DOI: 10.1021/acs.jmedchem.9b01502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
121 Soetens E, Ballegeer M, Saelens X. An Inside Job: Applications of Intracellular Single Domain Antibodies. Biomolecules 2020;10:E1663. [PMID: 33322697 DOI: 10.3390/biom10121663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
122 El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 2020;141:40-61. [PMID: 33125946 DOI: 10.1016/j.ejca.2020.09.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
123 Min W, He C, Zhang S, Zhao Y. c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma. Front Oncol 2021;11:602900. [PMID: 34367939 DOI: 10.3389/fonc.2021.602900] [Reference Citation Analysis]
124 Liang H, Du J, Elhassan RM, Hou X, Fang H. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opin Investig Drugs 2021;30:61-76. [PMID: 33183110 DOI: 10.1080/13543784.2021.1850693] [Reference Citation Analysis]
125 Du Y, Wang R. Revealing the Unbinding Kinetics and Mechanism of Type I and Type II Protein Kinase Inhibitors by Local-Scaled Molecular Dynamics Simulations. J Chem Theory Comput 2020;16:6620-32. [PMID: 32841004 DOI: 10.1021/acs.jctc.0c00342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Tang CP, Clark O, Ferrarone JR, Campos C, Lalani AS, Chodera JD, Intlekofer AM, Elemento O, Mellinghoff IK. GCN2 kinase activation by ATP-competitive kinase inhibitors. Nat Chem Biol 2021. [PMID: 34949839 DOI: 10.1038/s41589-021-00947-8] [Reference Citation Analysis]
127 Vagnarelli P, Alessi DR. PP1 Phosphatase Complexes: Undruggable No Longer. Cell 2018;174:1049-51. [PMID: 30142342 DOI: 10.1016/j.cell.2018.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
128 Karamafrooz A, Brennan J, Thomas DD, Parker LL. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (PRKACA) and Its Oncogenic Mutant DNAJB1-PRKACA. J Proteome Res 2021;20:4815-30. [PMID: 34436901 DOI: 10.1021/acs.jproteome.1c00500] [Reference Citation Analysis]
129 Teng Y, Lu K, Zhang Q, Zhao L, Huang Y, Ingarra AM, Galons H, Li T, Cui S, Yu P, Oumata N. Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry 2019;183:111641. [DOI: 10.1016/j.ejmech.2019.111641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
130 Lu T, Zhang L, Zhu W, Zhang Y, Zhang S, Wu B, Deng N. CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer. Front Oncol 2020;10:1529. [PMID: 32984003 DOI: 10.3389/fonc.2020.01529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Kasahara K, Re S, Nawrocki G, Oshima H, Mishima-Tsumagari C, Miyata-Yabuki Y, Kukimoto-Niino M, Yu I, Shirouzu M, Feig M, Sugita Y. Reduced efficacy of a Src kinase inhibitor in crowded protein solution. Nat Commun 2021;12:4099. [PMID: 34215742 DOI: 10.1038/s41467-021-24349-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Němec V, Hylsová M, Maier L, Flegel J, Sievers S, Ziegler S, Schröder M, Berger B, Chaikuad A, Valčíková B, Uldrijan S, Drápela S, Souček K, Waldmann H, Knapp S, Paruch K. Furo[3,2‐ b ]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angew Chem 2018;131:1074-8. [DOI: 10.1002/ange.201810312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
133 Panagopoulos I, Gorunova L, Andersen K, Tafjord S, Lund-Iversen M, Lobmaier I, Micci F, Heim S. Recurrent Fusion of the GRB2 Associated Binding Protein 1 (GAB1) Gene With ABL Proto-oncogene 1 (ABL1) in Benign Pediatric Soft Tissue Tumors. Cancer Genomics Proteomics 2020;17:499-508. [PMID: 32859628 DOI: 10.21873/cgp.20206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
134 Boni J, Rubio-Perez C, López-Bigas N, Fillat C, de la Luna S. The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities. Cancers (Basel) 2020;12:E2106. [PMID: 32751160 DOI: 10.3390/cancers12082106] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
135 Cromm PM, Samarasinghe KTG, Hines J, Crews CM. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. J Am Chem Soc 2018;140:17019-26. [DOI: 10.1021/jacs.8b08008] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 26.3] [Reference Citation Analysis]
136 Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, Milan DJ. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation 2020;142:2443-55. [PMID: 33092403 DOI: 10.1161/CIRCULATIONAHA.120.049210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
137 Xue B, Jordan B, Rizvi S, Naegle KM. KinPred: A unified and sustainable approach for harnessing proteome-level human kinase-substrate predictions. PLoS Comput Biol 2021;17:e1008681. [PMID: 33556051 DOI: 10.1371/journal.pcbi.1008681] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Bajinting A, Ng HL. Structural studies of full-length receptor tyrosine kinases and their implications for drug design. Adv Protein Chem Struct Biol 2021;124:311-36. [PMID: 33632469 DOI: 10.1016/bs.apcsb.2020.10.007] [Reference Citation Analysis]
139 Feral A, Laconde G, Amblard M, Masurier N. PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances. Adv Therap 2020;3:2000148. [DOI: 10.1002/adtp.202000148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Awoonor-Williams E, Rowley CN. Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton's Tyrosine Kinase. J Chem Inf Model 2021;61:5234-42. [PMID: 34590480 DOI: 10.1021/acs.jcim.1c00897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
142 Lambert LJ, Romero C, Sheffler DJ, Celeridad M, Cosford NDP, Tautz L. Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors. J Vis Exp 2020. [PMID: 32744526 DOI: 10.3791/61457] [Reference Citation Analysis]
143 Yang W, Freeman MR, Kyprianou N. Personalization of prostate cancer therapy through phosphoproteomics. Nat Rev Urol 2018;15:483-97. [PMID: 29752463 DOI: 10.1038/s41585-018-0014-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
144 Liu R, Zhan S, Che Y, Shen J. Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases. J Med Chem 2021. [PMID: 34647463 DOI: 10.1021/acs.jmedchem.1c01186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Roskoski R Jr. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). Pharmacol Res 2021;165:105422. [PMID: 33434619 DOI: 10.1016/j.phrs.2021.105422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
146 Das D, Hong J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. European Journal of Medicinal Chemistry 2019;170:55-72. [DOI: 10.1016/j.ejmech.2019.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
147 Jan H, Usman H, Shah M, Zaman G, Mushtaq S, Drouet S, Hano C, Abbasi BH. Phytochemical analysis and versatile in vitro evaluation of antimicrobial, cytotoxic and enzyme inhibition potential of different extracts of traditionally used Aquilegia pubiflora Wall. Ex Royle. BMC Complement Med Ther 2021;21:165. [PMID: 34098912 DOI: 10.1186/s12906-021-03333-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Shi Z, Li X, Wei M, Chen P, Zhang T, Ling X, Zhang J, Zhao C, Wang F, Liang G. Receptor tyrosine kinases-instructed release of its inhibitor from hydrogel to delay ovarian aging. Biomaterials 2021;269:120536. [PMID: 33248720 DOI: 10.1016/j.biomaterials.2020.120536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Li H, Lee CH, Shin I. A triple-targeting delivery system carrying two anticancer agents. Org Biomol Chem 2021;19:8009-13. [PMID: 34236071 DOI: 10.1039/d1ob01089a] [Reference Citation Analysis]
150 Romero C, Lambert LJ, Sheffler DJ, De Backer LJS, Raveendra-Panickar D, Celeridad M, Grotegut S, Rodiles S, Holleran J, Sergienko E, Pasquale EB, Cosford NDP, Tautz L. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors. J Biol Chem 2020;295:2601-13. [PMID: 31953320 DOI: 10.1074/jbc.RA119.010838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
151 Byrne DP, Li Y, Ramakrishnan K, Barsukov IL, Yates EA, Eyers CE, Papy-Garcia D, Chantepie S, Pagadala V, Liu J, Wells C, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA. New tools for carbohydrate sulfation analysis: heparan sulfate 2-O-sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitors. Biochem J 2018;475:2417-33. [PMID: 29934491 DOI: 10.1042/BCJ20180265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
152 Re S, Oshima H, Kasahara K, Kamiya M, Sugita Y. Encounter complexes and hidden poses of kinase-inhibitor binding on the free-energy landscape. Proc Natl Acad Sci U S A 2019;116:18404-9. [PMID: 31451651 DOI: 10.1073/pnas.1904707116] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
153 Siriwardena SU, Munkanatta Godage DNP, Shoba VM, Lai S, Shi M, Wu P, Chaudhary SK, Schreiber SL, Choudhary A. Phosphorylation-Inducing Chimeric Small Molecules. J Am Chem Soc 2020;142:14052-7. [DOI: 10.1021/jacs.0c05537] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
154 Hendrychová D, Jorda R, Kryštof V. How selective are clinical CDK4/6 inhibitors? Med Res Rev 2021;41:1578-98. [PMID: 33300617 DOI: 10.1002/med.21769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Elmenier FM, Lasheen DS, Abouzid KAM. Design, synthesis, and biological evaluation of new thieno[2,3-d] pyrimidine derivatives as targeted therapy for PI3K with molecular modelling study. J Enzyme Inhib Med Chem 2022;37:315-32. [PMID: 34955086 DOI: 10.1080/14756366.2021.2010729] [Reference Citation Analysis]
156 Kreuzer J, Edwards A, Haas W. Multiplexed quantitative phosphoproteomics of cell line and tissue samples. Post-translational Modifications That Modulate Enzyme Activity. Elsevier; 2019. pp. 41-65. [DOI: 10.1016/bs.mie.2019.07.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
157 Kakarala KK, Jamil K. Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach. J Biomol Struct Dyn 2021;:1-22. [PMID: 33682622 DOI: 10.1080/07391102.2021.1891140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Liu X, Long MJC, Aye Y. Proteomics and Beyond: Cell Decision-Making Shaped by Reactive Electrophiles. Trends Biochem Sci 2019;44:75-89. [PMID: 30327250 DOI: 10.1016/j.tibs.2018.09.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
159 Mansour HM, Fawzy HM, El-Khatib AS, Khattab MM. Lapatinib ditosylate rescues memory impairment in D-galactose/ovariectomized rats: Potential repositioning of an anti-cancer drug for the treatment of Alzheimer's disease. Exp Neurol 2021;341:113697. [PMID: 33727095 DOI: 10.1016/j.expneurol.2021.113697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Viengkhou B, White MY, Cordwell SJ, Campbell IL, Hofer MJ. A novel phosphoproteomic landscape evoked in response to type I interferon in the brain and in glial cells. J Neuroinflammation 2021;18:237. [PMID: 34656141 DOI: 10.1186/s12974-021-02277-x] [Reference Citation Analysis]
161 Naganuma M, Ohoka N, Tsuji G, Tsujimura H, Matsuno K, Inoue T, Naito M, Demizu Y. Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.1c00629] [Reference Citation Analysis]
162 Carnero Contentti E, Correale J. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs 2020;25:377-81. [PMID: 32910702 DOI: 10.1080/14728214.2020.1822817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
163 Jiang H, Jin Y, Yan H, Xu Z, Yang B, He Q, Luo P. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Expert Opin Drug Saf 2021;20:335-48. [PMID: 33356646 DOI: 10.1080/14740338.2021.1867104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Xu C, Wang S, Wu Y, Sun X, Yang D, Wang S. Recent advances in understanding the roles of sialyltransferases in tumor angiogenesis and metastasis. Glycoconj J 2021;38:119-27. [PMID: 33411077 DOI: 10.1007/s10719-020-09967-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Hitz E, Grüninger O, Passecker A, Wyss M, Scheurer C, Wittlin S, Beck HP, Brancucci NMB, Voss TS. The catalytic subunit of Plasmodium falciparum casein kinase 2 is essential for gametocytogenesis. Commun Biol 2021;4:336. [PMID: 33712726 DOI: 10.1038/s42003-021-01873-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Zhang Y, Rong D, Li B, Wang Y. Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors. J Med Chem 2021;64:7900-25. [PMID: 33599482 DOI: 10.1021/acs.jmedchem.0c02055] [Reference Citation Analysis]
167 Garrido A, Vera G, Delaye PO, Enguehard-Gueiffier C. Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review. Eur J Med Chem 2021;226:113867. [PMID: 34607244 DOI: 10.1016/j.ejmech.2021.113867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Schmitt DL, Mehta S, Zhang J. Illuminating the kinome: Visualizing real-time kinase activity in biological systems using genetically encoded fluorescent protein-based biosensors. Curr Opin Chem Biol 2020;54:63-9. [PMID: 31911398 DOI: 10.1016/j.cbpa.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Lambert LJ, Grotegut S, Celeridad M, Gosalia P, Backer LJ, Bobkov AA, Salaniwal S, Chung TD, Zeng FY, Pass I, Lombroso PJ, Cosford ND, Tautz L. Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP). Int J Mol Sci 2021;22:4417. [PMID: 33922601 DOI: 10.3390/ijms22094417] [Reference Citation Analysis]
170 Mansour HM, Fawzy HM, El-Khatib AS, Khattab MM. Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer's Disease: Current Perspectives and Challenging Prospects. Neuroscience 2021;469:191-6. [PMID: 34139302 DOI: 10.1016/j.neuroscience.2021.06.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Karatas M, Chaikuad A, Berger B, Kubbutat MHG, Totzke F, Knapp S, Kunick C. 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a "Cut and Glue" Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors. Molecules 2021;26:1611. [PMID: 33799460 DOI: 10.3390/molecules26061611] [Reference Citation Analysis]
172 Sinclair JKL, Robertson WE, Mozumdar D, Quach K, Schepartz A. Allosteric Inhibition of the Epidermal Growth Factor Receptor. Biochemistry 2021;60:500-12. [PMID: 33557518 DOI: 10.1021/acs.biochem.0c00978] [Reference Citation Analysis]
173 Cole PA, Chu N, Salguero AL, Bae H. AKTivation mechanisms. Curr Opin Struct Biol 2019;59:47-53. [PMID: 30901610 DOI: 10.1016/j.sbi.2019.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
174 Ansar S, Vetrivel U. KinomeRun: An interactive utility for kinome target screening and interaction fingerprint analysis towards holistic visualization on kinome tree. Chem Biol Drug Des 2020;96:1162-75. [PMID: 32418310 DOI: 10.1111/cbdd.13705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Saarbach J, Barluenga S, Winssinger N. PNA-Encoded Synthesis (PES) and DNA Display of Small Molecule Libraries. Methods Mol Biol 2020;2105:119-39. [PMID: 32088867 DOI: 10.1007/978-1-0716-0243-0_7] [Reference Citation Analysis]
176 Umezawa K, Kii I. Druggable Transient Pockets in Protein Kinases. Molecules 2021;26:651. [PMID: 33513739 DOI: 10.3390/molecules26030651] [Reference Citation Analysis]
177 Pegram LM, Anderson JW, Ahn NG. Dynamic equilibria in protein kinases. Curr Opin Struct Biol 2021;71:215-22. [PMID: 34425481 DOI: 10.1016/j.sbi.2021.07.006] [Reference Citation Analysis]
178 Hu H, Bajorath J. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors. Bioorg Med Chem 2021;41:116226. [PMID: 34082305 DOI: 10.1016/j.bmc.2021.116226] [Reference Citation Analysis]
179 Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, Spillmann M, Berger P, Schibli R, Behe M. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N. Theranostics 2020;10:10861-73. [PMID: 33042258 DOI: 10.7150/thno.45440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Naito M, Ohoka N, Shibata N, Tsukumo Y. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs. Front Chem 2019;7:849. [PMID: 31921772 DOI: 10.3389/fchem.2019.00849] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
181 Zhang L, Chen X, Deng Y, Jiang C, Deng N. Fermentation, purification and immunogenicity of a recombinant tumor multi-epitope vaccine, VBP3. Protein Expr Purif 2020;174:105658. [PMID: 32360598 DOI: 10.1016/j.pep.2020.105658] [Reference Citation Analysis]
182 Cook SJ, Tucker JA, Lochhead PA. Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for…. Biochem Soc Trans 2020;48:1859-75. [PMID: 32915196 DOI: 10.1042/BST20190338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
183 Natividad LA, Buczynski MW, McClatchy DB, Yates JR 3rd. From Synapse to Function: A Perspective on the Role of Neuroproteomics in Elucidating Mechanisms of Drug Addiction. Proteomes 2018;6:50. [PMID: 30544849 DOI: 10.3390/proteomes6040050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
184 De Vita E. 10 years into the resurgence of covalent drugs. Future Med Chem 2021;13:193-210. [PMID: 33275063 DOI: 10.4155/fmc-2020-0236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
185 Miller MS, Thompson PE, Gabelli SB. Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules 2019;9:E82. [PMID: 30813656 DOI: 10.3390/biom9030082] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
186 Martín-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 2021;210:112993. [PMID: 33189436 DOI: 10.1016/j.ejmech.2020.112993] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
187 Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context 2019;8:212595. [PMID: 31692920 DOI: 10.7573/dic.212595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
188 Zarrin AA, Bao K, Lupardus P, Vucic D. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov 2021;20:39-63. [PMID: 33077936 DOI: 10.1038/s41573-020-0082-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
189 Tucholski T, Ge Y. Fourier-transform ion cyclotron resonance mass spectrometry for characterizing proteoforms. Mass Spectrom Rev 2020. [PMID: 32894796 DOI: 10.1002/mas.21653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Thomson DW, Poeckel D, Zinn N, Rau C, Strohmer K, Wagner AJ, Graves AP, Perrin J, Bantscheff M, Duempelfeld B, Kasparcova V, Ramanjulu JM, Pesiridis GS, Muelbaier M, Bergamini G. Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Med Chem Lett 2019;10:780-5. [PMID: 31097999 DOI: 10.1021/acsmedchemlett.9b00027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
191 Lin J, Jin J, Shen Y, Zhang L, Gong G, Bian H, Chen H, Nagle DG, Wu Y, Zhang W, Luan X. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics 2021;11:8337-49. [PMID: 34373745 DOI: 10.7150/thno.62686] [Reference Citation Analysis]
192 Wei L, Adderley J, Leroy D, Drewry DH, Wilson DW, Kaushansky A, Doerig C. Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Rep Med 2021;2:100423. [PMID: 34693368 DOI: 10.1016/j.xcrm.2021.100423] [Reference Citation Analysis]
193 Awoonor-williams E, Rowley CN. How Reactive are Druggable Cysteines in Protein Kinases? J Chem Inf Model 2018;58:1935-46. [DOI: 10.1021/acs.jcim.8b00454] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
194 Ma D, Chen X, Shen X, Sheng LQ, Liu XH. Binding patterns and structure–activity relationship of CDK8 inhibitors. Bioorganic Chemistry 2020;96:103624. [DOI: 10.1016/j.bioorg.2020.103624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Catta-Preta CMC, Mottram JC. Drug candidate and target for leishmaniasis. Nature 2018;560:171-2. [PMID: 30076375 DOI: 10.1038/d41586-018-05765-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
196 Elkoshi Z. The Binary Classification of Protein Kinases. J Inflamm Res 2021;14:929-47. [PMID: 33776467 DOI: 10.2147/JIR.S303750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Bernard-Gauthier V, Mossine AV, Knight A, Patnaik D, Zhao WN, Cheng C, Krishnan HS, Xuan LL, Chindavong PS, Reis SA, Chen JM, Shao X, Stauff J, Arteaga J, Sherman P, Salem N, Bonsall D, Amaral B, Varlow C, Wells L, Martarello L, Patel S, Liang SH, Kurumbail RG, Haggarty SJ, Scott PJH, Vasdev N. Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery. J Med Chem 2019;62:9600-17. [PMID: 31535859 DOI: 10.1021/acs.jmedchem.9b01030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
198 Guimarães TR, Swanson E, Kofler J, Thathiah A. G protein-coupled receptor kinases are associated with Alzheimer's disease pathology. Neuropathol Appl Neurobiol 2021. [PMID: 34164834 DOI: 10.1111/nan.12742] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Atzeni F, Masala IF, Rodríguez-Carrio J, Ríos-Garcés R, Gerratana E, La Corte L, Giallanza M, Nucera V, Riva A, Espinosa G, Cervera R. The Rheumatology Drugs for COVID-19 Management: Which and When? J Clin Med 2021;10:783. [PMID: 33669218 DOI: 10.3390/jcm10040783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
200 Bum-Erdene K, Liu D, Gonzalez-Gutierrez G, Ghozayel MK, Xu D, Meroueh SO. Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases. Proc Natl Acad Sci U S A 2020;117:7131-9. [PMID: 32179690 DOI: 10.1073/pnas.1913654117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
201 Chen S, Wiewiora RP, Meng F, Babault N, Ma A, Yu W, Qian K, Hu H, Zou H, Wang J, Fan S, Blum G, Pittella-Silva F, Beauchamp KA, Tempel W, Jiang H, Chen K, Skene RJ, Zheng YG, Brown PJ, Jin J, Luo C, Chodera JD, Luo M. The dynamic conformational landscape of the protein methyltransferase SETD8. Elife 2019;8:e45403. [PMID: 31081496 DOI: 10.7554/eLife.45403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
202 Kinoh H, Shibasaki H, Liu X, Yamasoba T, Cabral H, Kataoka K. Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. Journal of Controlled Release 2020;321:132-44. [DOI: 10.1016/j.jconrel.2020.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
203 Borba JVVB, Silva AC, Lima MNN, Mendonca SS, Furnham N, Costa FTM, Andrade CH. Chemogenomics and bioinformatics approaches for prioritizing kinases as drug targets for neglected tropical diseases. Adv Protein Chem Struct Biol 2021;124:187-223. [PMID: 33632465 DOI: 10.1016/bs.apcsb.2020.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Jaeger MG, Winter GE. Fast-acting chemical tools to delineate causality in transcriptional control. Mol Cell 2021;81:1617-30. [PMID: 33689749 DOI: 10.1016/j.molcel.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Fu J, Xie Y, Fu T, Qiu F, Yu F, Qu W, Yao X, Zhang A, Yang Z, Shao G, Meng Q, Shi X, Huang Y, Gu W, Wang F. [99mTc]Tc-Galacto-RGD2 integrin αvβ3-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data. EJNMMI Res 2021;11:59. [PMID: 34121134 DOI: 10.1186/s13550-021-00801-x] [Reference Citation Analysis]
206 Machado CB, de Pinho Pessoa FMC, da Silva EL, da Costa Pantoja L, Ribeiro RM, de Moraes Filho MO, de Moraes MEA, Montenegro RC, Burbano RMR, Khayat AS, Moreira-Nunes CA. Kinase Inhibition in Relapsed/Refractory Leukemia and Lymphoma Settings: Recent Prospects into Clinical Investigations. Pharmaceutics 2021;13:1604. [PMID: 34683897 DOI: 10.3390/pharmaceutics13101604] [Reference Citation Analysis]
207 Wein MN, Foretz M, Fisher DE, Xavier RJ, Kronenberg HM. Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab 2018;29:723-35. [PMID: 30150136 DOI: 10.1016/j.tem.2018.08.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 11.8] [Reference Citation Analysis]
208 Wang Z, Huang W, Zhou K, Ren X, Ding K. Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? J Med Chem 2022. [PMID: 35000385 DOI: 10.1021/acs.jmedchem.1c01978] [Reference Citation Analysis]
209 Asquith CRM, Maffuid KA, Laitinen T, Torrice CD, Tizzard GJ, Crona DJ, Zuercher WJ. Targeting an EGFR Water Network with 4‐Anilinoquin(az)oline Inhibitors for Chordoma. ChemMedChem 2019;14:1693-700. [DOI: 10.1002/cmdc.201900428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
210 Li J, Zheng C, Wang M, Umano AD, Dai Q, Zhang C, Huang H, Yang Q, Yang X, Lu J, Pan W, Li B, Yao S, Pan C. ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer. Oncogene 2022. [PMID: 35039634 DOI: 10.1038/s41388-021-02149-x] [Reference Citation Analysis]
211 Rajić KPZ, Mlinarić Z, Uzelac L, Kralj M, Zorc B. Chloroquine Urea Derivatives: Synthesis and Antitumor Activity in Vitro. Acta Pharm 2018;68:471-83. [PMID: 31259711 DOI: 10.2478/acph-2018-0039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
212 Sokolov AV, Dostdar SA, Attwood MM, Krasilnikova AA, Ilina AA, Nabieva AS, Lisitsyna AA, Chubarev VN, Tarasov VV, Schiöth HB. Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies. Pharmacol Rev 2021;73:1-32. [PMID: 34663683 DOI: 10.1124/pharmrev.121.000317] [Reference Citation Analysis]
213 Wu Z, Jin Y, Chen B, Gugger MK, Wilkinson-Johnson CL, Tiambeng TN, Jin S, Ge Y. Comprehensive Characterization of the Recombinant Catalytic Subunit of cAMP-Dependent Protein Kinase by Top-Down Mass Spectrometry. J Am Soc Mass Spectrom 2019;30:2561-70. [PMID: 31792770 DOI: 10.1007/s13361-019-02341-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
214 Chen Z, Ma D. Cu/ N , N ′-Dibenzyloxalamide-Catalyzed N -Arylation of Heteroanilines. Org Lett 2019;21:6874-8. [DOI: 10.1021/acs.orglett.9b02509] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
215 Golkowski M, Vidadala VN, Lau HT, Shoemaker A, Shimizu-Albergine M, Beavo J, Maly DJ, Ong SE. Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks. J Proteome Res 2020;19:1235-47. [PMID: 32037842 DOI: 10.1021/acs.jproteome.9b00742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
216 Yu Q, Sun Y. Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start? Drug Des Devel Ther 2021;15:1-8. [PMID: 33442232 DOI: 10.2147/DDDT.S286373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M, Chan DW, Nesvizhskii AI, Wang P, Zhang H; Clinical Proteomic Tumor Analysis Consortium. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 2019;179:964-983.e31. [PMID: 31675502 DOI: 10.1016/j.cell.2019.10.007] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 55.5] [Reference Citation Analysis]
218 Ahmed A, Raja VJ, Cavaliere P, Dephoure N. Robust, Reproducible, and Economical Phosphopeptide Enrichment Using Calcium Titanate. J Proteome Res 2019;18:1411-7. [DOI: 10.1021/acs.jproteome.8b00883] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Kwofie SK, Broni E, Dankwa B, Enninful KS, Kwarko GB, Darko L, Durvasula R, Kempaiah P, Rathi B, Miller Iii WA, Yaya A, Wilson MD. Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential. Curr Top Med Chem 2020;20:349-66. [PMID: 31994465 DOI: 10.2174/1568026620666200128160454] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
220 Chen X, Xie B, Huang L, Wan J, Wang Y, Shi X, Qiao Y, Song H, Wang H. Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy. Theranostics 2021;11:5713-27. [PMID: 33897877 DOI: 10.7150/thno.55250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Farag AK, Roh EJ. Death-associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes. Med Res Rev 2019;39:349-85. [DOI: 10.1002/med.21518] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
222 Groppe JC. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. Expert Opinion on Drug Discovery 2019;14:1237-53. [DOI: 10.1080/17460441.2019.1660641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
223 Shindo N, Ojida A. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Bioorg Med Chem 2021;47:116386. [PMID: 34509863 DOI: 10.1016/j.bmc.2021.116386] [Reference Citation Analysis]
224 Asquith CRM, Laitinen T, Bennett JM, Wells CI, Elkins JM, Zuercher WJ, Tizzard GJ, Poso A. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships. ChemMedChem 2020;15:26-49. [PMID: 31675459 DOI: 10.1002/cmdc.201900521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
225 Tutusaus A, de Gregorio E, Cucarull B, Cristóbal H, Aresté C, Graupera I, Coll M, Colell A, Gausdal G, Lorens JB, García de Frutos P, Morales A, Marí M. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cell Mol Gastroenterol Hepatol 2020;9:349-68. [PMID: 31689560 DOI: 10.1016/j.jcmgh.2019.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
226 Giunta M, Solje E, Gardoni F, Borroni B, Benussi A. Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration. J Exp Pharmacol 2021;13:359-76. [PMID: 33790662 DOI: 10.2147/JEP.S262352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol 2019;19:734-46. [PMID: 31501536 DOI: 10.1038/s41577-019-0213-9] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 29.0] [Reference Citation Analysis]
228 Grigglestone CE, Yeung KS. Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity. ACS Med Chem Lett 2021;12:1629-32. [PMID: 34795847 DOI: 10.1021/acsmedchemlett.1c00543] [Reference Citation Analysis]
229 Porębska N, Poźniak M, Matynia A, Żukowska D, Zakrzewska M, Otlewski J, Opaliński Ł. Galectins as modulators of receptor tyrosine kinases signaling in health and disease. Cytokine Growth Factor Rev 2021;60:89-106. [PMID: 33863623 DOI: 10.1016/j.cytogfr.2021.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Das R, Choithramani A, Shard A. A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics. Drug Discov Today 2021:S1359-6446(21)00543-2. [PMID: 34920095 DOI: 10.1016/j.drudis.2021.12.009] [Reference Citation Analysis]
231 Ye Z, Wang Y, Wu H, Song T, Li X, Liu Q, Wang C. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair. Chembiochem 2021;22:129-33. [PMID: 32979005 DOI: 10.1002/cbic.202000527] [Reference Citation Analysis]
232 Meng F, Liang Z, Zhao K, Luo C. Drug design targeting active posttranslational modification protein isoforms. Med Res Rev 2021;41:1701-50. [PMID: 33355944 DOI: 10.1002/med.21774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
233 Němec V, Hylsová M, Maier L, Flegel J, Sievers S, Ziegler S, Schröder M, Berger BT, Chaikuad A, Valčíková B, Uldrijan S, Drápela S, Souček K, Waldmann H, Knapp S, Paruch K. Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angew Chem Int Ed Engl 2019;58:1062-6. [PMID: 30569600 DOI: 10.1002/anie.201810312] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
234 Subramanian G, Zhu Y, Bowen SJ, Roush N, White JA, Huczek D, Zachary T, Javens C, Williams T, Janssen A, Gonzales A. Lead identification and characterization of hTrkA type 2 inhibitors. Bioorg Med Chem Lett 2019;29:126680. [PMID: 31610943 DOI: 10.1016/j.bmcl.2019.126680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
235 Murugesan S, Murugesan J, Palaniappan S, Palaniappan S, Murugan T, Siddiqui SS, Loganathan S. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Curr Cancer Drug Targets 2021;21:55-69. [PMID: 33038912 DOI: 10.2174/1568009620666201009130008] [Reference Citation Analysis]
236 Paludetto M, Puisset F, Chatelut E, Arellano C. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Med Res Rev 2019;39:2105-52. [DOI: 10.1002/med.21577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
237 Modi V, Dunbrack RL. Kincore: a web resource for structural classification of protein kinases and their inhibitors. Nucleic Acids Res 2021:gkab920. [PMID: 34643709 DOI: 10.1093/nar/gkab920] [Reference Citation Analysis]
238 Lu T, Chen C, Wang A, Jiang Z, Qi Z, Hu Z, Hu C, Liu F, Wang W, Wu H, Wang B, Wang L, Qi S, Wu J, Wang W, Tang J, Yan H, Bai M, Liu Q, Liu J. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. Cancer Lett 2019;447:105-14. [PMID: 30684595 DOI: 10.1016/j.canlet.2019.01.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
239 Glennon EKK, Dankwa S, Smith JD, Kaushansky A. Opportunities for Host-targeted Therapies for Malaria. Trends Parasitol 2018;34:843-60. [PMID: 30122551 DOI: 10.1016/j.pt.2018.07.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
240 Poganik JR, Huang KT, Parvez S, Zhao Y, Raja S, Long MJC, Aye Y. Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera. Nat Commun 2021;12:5736. [PMID: 34593792 DOI: 10.1038/s41467-021-25466-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Nielsen SR, Strøbech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, Maltese G, Jensen ARD, Reuten R, Rafaeva M, Karim SA, Hwang CI, Arnes L, Tuveson DA, Sansom OJ, Morton JP, Erler JT. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nat Commun 2021;12:3414. [PMID: 34099731 DOI: 10.1038/s41467-021-23731-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
242 Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmuller P, Pullamsetti SS, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT. Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nat Commun 2019;10:2204. [PMID: 31101827 DOI: 10.1038/s41467-019-10135-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
243 Laufkötter O, Laufer S, Bajorath J. Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. European Journal of Medicinal Chemistry 2020;204:112641. [DOI: 10.1016/j.ejmech.2020.112641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Tabtimmai L, Suphakun P, Srisook P, Kiriwan D, Phanthong S, Kiatwuthinon P, Chaicumpa W, Choowongkomon K. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. J Cell Biochem 2019;120:18077-87. [PMID: 31172597 DOI: 10.1002/jcb.29111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
245 Dhokne P, Sakla AP, Shankaraiah N. Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. Eur J Med Chem 2021;216:113334. [PMID: 33721669 DOI: 10.1016/j.ejmech.2021.113334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
246 Xiong Y, Li M, Lu W, Wang D, Tang M, Liu Y, Na B, Qin H, Qing G. Discerning Tyrosine Phosphorylation from Multiple Phosphorylations Using a Nanofluidic Logic Platform. Anal Chem 2021;93:16113-22. [PMID: 34841853 DOI: 10.1021/acs.analchem.1c03889] [Reference Citation Analysis]
247 Martin RD, Hébert TE, Tanny JC. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery. Int J Mol Sci 2020;21:E3354. [PMID: 32397434 DOI: 10.3390/ijms21093354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
248 Wang B, Wu H, Hu C, Wang H, Liu J, Wang W, Liu Q. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther 2021;6:423. [PMID: 34924565 DOI: 10.1038/s41392-021-00826-7] [Reference Citation Analysis]
249 Bryce NS, Hardeman EC, Gunning PW, Lock JG. Chemical biology approaches targeting the actin cytoskeleton through phenotypic screening. Curr Opin Chem Biol 2019;51:40-7. [PMID: 30901618 DOI: 10.1016/j.cbpa.2019.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
250 Imran M, Asdaq SMB, Khan SA, Unnikrishnan Meenakshi D, Alamri AS, Alsanie WF, Alhomrani M, Mohzari Y, Alrashed A, AlMotairi M, Alkhaldi EH, Alorabi AK, Alshrari AS, Tauseef M, Abida, Alaqel SI, Alam O, Bakht MA. Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades. Pharmaceuticals (Basel) 2021;14:710. [PMID: 34451807 DOI: 10.3390/ph14080710] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Shen C, Wang Z, Yao X, Li Y, Lei T, Wang E, Xu L, Zhu F, Li D, Hou T. Comprehensive assessment of nine docking programs on type II kinase inhibitors: prediction accuracy of sampling power, scoring power and screening power. Briefings in Bioinformatics 2018. [DOI: 10.1093/bib/bby103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
252 Liu X, Li W, Zhang Y, Jiang Y, Zhao Q, Zhong D. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2019;176:112735. [DOI: 10.1016/j.jpba.2019.06.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
253 Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020;39:1179-203. [PMID: 32894370 DOI: 10.1007/s10555-020-09925-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
254 Shawky AM, Ibrahim NA, Abourehab MAS, Abdalla AN, Gouda AM. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. J Enzyme Inhib Med Chem 2021;36:15-33. [PMID: 33103497 DOI: 10.1080/14756366.2020.1837124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
255 Asquith CRM, Laitinen T, Wells CI, Tizzard GJ, Zuercher WJ. New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K). Molecules 2020;25:E1697. [PMID: 32272798 DOI: 10.3390/molecules25071697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
256 Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12/13 inhibition for the treatment of cancer. Future Med Chem 2021;13:117-41. [PMID: 33295810 DOI: 10.4155/fmc-2020-0240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
257 Hirozane Y, Toyofuku M, Yogo T, Tanaka Y, Sameshima T, Miyahisa I, Yoshikawa M. Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application. Bioorg Med Chem Lett 2019;29:126641. [PMID: 31526603 DOI: 10.1016/j.bmcl.2019.126641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
258 Lai V, Neshat SY, Rakoski A, Pitingolo J, Sabedra J, Li S, Shodhan A, Doloff JC. Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. Cell Mol Bioeng 2021;14:471-86. [PMID: 34777605 DOI: 10.1007/s12195-021-00708-6] [Reference Citation Analysis]
259 Du Y, Yan D, Yuan Y, Xu J, Wang S, Yang Z, Cheng W, Tian X, Kan Q. CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. Cell Cycle 2019;18:452-66. [PMID: 30722725 DOI: 10.1080/15384101.2019.1577665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
260 Blumcke I, Budday S, Poduri A, Lal D, Kobow K, Baulac S. Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. Lancet Neurol 2021;20:943-55. [PMID: 34687638 DOI: 10.1016/S1474-4422(21)00265-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Ferguson FM, Doctor ZM, Ficarro SB, Browne CM, Marto JA, Johnson JL, Yaron TM, Cantley LC, Kim ND, Sim T, Berberich MJ, Kalocsay M, Sorger PK, Gray NS. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chem Biol 2019;26:804-817.e12. [PMID: 30930164 DOI: 10.1016/j.chembiol.2019.02.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
262 Safabakhsh S, Panwar P, Barichello S, Sangha SS, Hanson PJ, Van Petegem F, Laksman Z. THE ROLE OF PHOSPHORYLATION IN ATRIAL FIBRILLATION: A FOCUS ON MASS SPECTROMETRY APPROACHES. Cardiovasc Res 2021:cvab095. [PMID: 33744917 DOI: 10.1093/cvr/cvab095] [Reference Citation Analysis]
263 Ray S, Lach R, Heesom KJ, Valekunja UK, Encheva V, Snijders AP, Reddy AB. Phenotypic proteomic profiling identifies a landscape of targets for circadian clock-modulating compounds. Life Sci Alliance 2019;2:e201900603. [PMID: 31792063 DOI: 10.26508/lsa.201900603] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
264 Erbay TG, Dempe DP, Godugu B, Liu P, Brummond KM. Thiol Reactivity of N-Aryl α-Methylene-γ-lactams: A Reactive Group for Targeted Covalent Inhibitor Design. J Org Chem 2021;86:11926-36. [PMID: 34379423 DOI: 10.1021/acs.joc.1c01335] [Reference Citation Analysis]
265 Ti H, Zhou Y, Liang X, Li R, Ding K, Zhao X. Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). J Med Chem 2019;62:5944-78. [PMID: 30682248 DOI: 10.1021/acs.jmedchem.8b01520] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
266 Dal corso A, Catalano M, Schmid A, Scheuermann J, Neri D. Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues. Angew Chem Int Ed 2018;57:17178-82. [DOI: 10.1002/anie.201811650] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
267 Zhao G, Gong L, Su D, Jin Y, Guo C, Yue M, Yao S, Qin Z, Ye Y, Tang Y, Wu Q, Zhang J, Cui B, Ding Q, Huang H, Hu L, Chen Y, Zhang P, Hu G, Chen L, Wong KK, Gao D, Ji H. Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1. J Clin Invest 2019;129:972-87. [PMID: 30688657 DOI: 10.1172/JCI122779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
268 Chakraborty S, Inukai T, Fang L, Golkowski M, Maly DJ. Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. ACS Chem Biol 2019;14:1249-59. [PMID: 31038916 DOI: 10.1021/acschembio.9b00214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
269 Jacobsen ED, Weinstock DM. Challenges and implications of genomics for T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2018;2018:63-8. [PMID: 30504292 DOI: 10.1182/asheducation-2018.1.63] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
270 Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B 2020;10:569-81. [PMID: 32322463 DOI: 10.1016/j.apsb.2019.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
271 Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018;11:120. [PMID: 30231931 DOI: 10.1186/s13045-018-0664-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 90] [Article Influence: 20.8] [Reference Citation Analysis]
272 Bansal R, Malhotra A. Therapeutic progression of quinazolines as targeted chemotherapeutic agents. Eur J Med Chem 2021;211:113016. [PMID: 33243532 DOI: 10.1016/j.ejmech.2020.113016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
273 Wang Z, Lian LJ, Dong YY, Cui X, Qian JC, Huang CK, Chen RJ, Sun W. Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study. J Anal Methods Chem 2019;2019:5016757. [PMID: 31886022 DOI: 10.1155/2019/5016757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
274 Gardner TJ, Bourne CM, Dacek MM, Kurtz K, Malviya M, Peraro L, Silberman PC, Vogt KC, Unti MJ, Brentjens R, Scheinberg D. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers (Basel) 2020;12:E2175. [PMID: 32764348 DOI: 10.3390/cancers12082175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
275 Okuno H, Okuzono H, Hayase A, Kumagai F, Tanii S, Hino N, Okada Y, Tachibana K, Doi T, Ishimoto K. Lipin-1 is a novel substrate of protein phosphatase PGAM5. Biochem Biophys Res Commun 2019;509:886-91. [PMID: 30642635 DOI: 10.1016/j.bbrc.2019.01.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
276 Fischer A, Sellner M, Mitusińska K, Bzówka M, Lill MA, Góra A, Smieško M. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. Int J Mol Sci 2021;22:2065. [PMID: 33669738 DOI: 10.3390/ijms22042065] [Reference Citation Analysis]
277 Guo W, Vandoorne T, Steyaert J, Staats KA, Van Den Bosch L. The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications. Brain 2020;143:1651-73. [PMID: 32206784 DOI: 10.1093/brain/awaa022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
278 Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, Shaham M, Rivlin A, Omer I, Zinger A, Elias S, Winter E, Erdman PE, Sullivan RW, Fung L, Mercurio F, Li D, Vacca J, Kaushansky N, Shlush L, Oren M, Levine R, Pikarsky E, Snir-Alkalay I, Ben-Neriah Y. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell 2018;175:171-185.e25. [PMID: 30146162 DOI: 10.1016/j.cell.2018.07.045] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
279 Zachari M, Rainard JM, Pandarakalam GC, Robinson L, Gillespie J, Rajamanickam M, Hamon V, Morrison A, Ganley IG, McElroy SP. The identification and characterisation of autophagy inhibitors from the published kinase inhibitor sets. Biochem J 2020;477:801-14. [PMID: 32011652 DOI: 10.1042/BCJ20190846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
280 Liu Q, Wang JCY, Xie SZ. SUMO wrestling cancer stem cells. Cell Chem Biol 2021;28:1390-2. [PMID: 34678166 DOI: 10.1016/j.chembiol.2021.10.001] [Reference Citation Analysis]
281 Byrne DP, Li Y, Ngamlert P, Ramakrishnan K, Eyers CE, Wells C, Drewry DH, Zuercher WJ, Berry NG, Fernig DG, Eyers PA. New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors. Biochem J 2018;475:2435-55. [PMID: 29934490 DOI: 10.1042/BCJ20180266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
282 Mashelkar KK, Byun WS, Ko H, Sung K, Tripathi SK, An S, Yum YA, Kwon JY, Kim M, Kim G, Kwon EJ, Lee HW, Noh M, Lee SK, Jeong LS. Discovery of a Novel Template, 7-Substituted 7-Deaza-4'-Thioadenosine Derivatives as Multi-Kinase Inhibitors. Pharmaceuticals (Basel) 2021;14:1290. [PMID: 34959689 DOI: 10.3390/ph14121290] [Reference Citation Analysis]
283 Cheng M, Yu X, Lu K, Xie L, Wang L, Meng F, Han X, Chen X, Liu J, Xiong Y, Jin J. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. J Med Chem 2020;63:1216-32. [PMID: 31895569 DOI: 10.1021/acs.jmedchem.9b01566] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
284 Fu SY, Wang CC, Chen FH, Yu CF, Hong JH, Chiang CS. Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells. In Vivo 2020;34:1141-52. [PMID: 32354903 DOI: 10.21873/invivo.11886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
285 Morgan D, Berggren KL, Spiess CD, Smith HM, Tejwani A, Weir SJ, Lominska CE, Thomas SM, Gan GN. Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer. Mol Carcinog 2021. [PMID: 34559922 DOI: 10.1002/mc.23348] [Reference Citation Analysis]
286 Li T, Wang N, Zhang T, Zhang B, Sajeevan TP, Joseph V, Armstrong L, He S, Yan X, Naman CB. A Systematic Review of Recently Reported Marine Derived Natural Product Kinase Inhibitors. Mar Drugs 2019;17:E493. [PMID: 31450856 DOI: 10.3390/md17090493] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
287 Ferraro M, D’annessa I, Moroni E, Morra G, Paladino A, Rinaldi S, Compostella F, Colombo G. Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design. J Med Chem 2019;62:60-87. [DOI: 10.1021/acs.jmedchem.8b00825] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
288 King A, Blackledge MS. Evaluation of small molecule kinase inhibitors as novel antimicrobial and antibiofilm agents. Chem Biol Drug Des 2021;98:1038-64. [PMID: 34581492 DOI: 10.1111/cbdd.13962] [Reference Citation Analysis]
289 Wojewska DN, Kortholt A. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease. Biomolecules 2021;11:1101. [PMID: 34439767 DOI: 10.3390/biom11081101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Wang H, Song L, Zhou T, Zeng C, Jia Y, Zhao Y. A computational study of Tat-CDK9-Cyclin binding dynamics and its implication in transcription-dependent HIV latency. Phys Chem Chem Phys 2020;22:25474-82. [PMID: 33043947 DOI: 10.1039/d0cp03662e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
291 Pisa R, Cupido T, Steinman JB, Jones NH, Kapoor TM. Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins. Cell Chem Biol 2019;26:1263-1273.e5. [PMID: 31257183 DOI: 10.1016/j.chembiol.2019.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
292 Kramer MM, Mühlhäuser WWD, Weber W, Radziwill G. Multichromatic Control of Signaling Pathways in Mammalian Cells. Adv Biol (Weinh) 2021;5:e2000196. [PMID: 33045139 DOI: 10.1002/adbi.202000196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
293 Asquith CRM, Fleck N, Torrice CD, Crona DJ, Grundner C, Zuercher WJ. Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines. Bioorg Med Chem Lett 2019;29:2695-9. [PMID: 31378571 DOI: 10.1016/j.bmcl.2019.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
294 Jurcik J, Sivakova B, Cipakova I, Selicky T, Stupenova E, Jurcik M, Osadska M, Barath P, Cipak L. Phosphoproteomics Meets Chemical Genetics: Approaches for Global Mapping and Deciphering the Phosphoproteome. Int J Mol Sci 2020;21:E7637. [PMID: 33076458 DOI: 10.3390/ijms21207637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater 2021;6:351-70. [DOI: 10.1038/s41578-020-00269-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 21.0] [Reference Citation Analysis]
296 Gharibi T, Babaloo Z, Hosseini A, Abdollahpour-alitappeh M, Hashemi V, Marofi F, Nejati K, Baradaran B. Targeting STAT3 in cancer and autoimmune diseases. European Journal of Pharmacology 2020;878:173107. [DOI: 10.1016/j.ejphar.2020.173107] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
297 Chiurillo MA, Jensen BC, Docampo R. Drug Target Validation of the Protein Kinase AEK1, Essential for Proliferation, Host Cell Invasion, and Intracellular Replication of the Human Pathogen Trypanosoma cruzi. Microbiol Spectr 2021;9:e0073821. [PMID: 34585973 DOI: 10.1128/Spectrum.00738-21] [Reference Citation Analysis]
298 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Bishop TR, Zhang Y, Erb MA. Pharmacological Modulation of Transcriptional Coregulators in Cancer. Trends Pharmacol Sci 2019;40:388-402. [PMID: 31078321 DOI: 10.1016/j.tips.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
300 Spagnuolo A, Palazzolo G, Sementa C, Gridelli C. Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer. Expert Opinion on Pharmacotherapy 2020;21:491-506. [DOI: 10.1080/14656566.2020.1713092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
301 Durai P, Ko YJ, Pan CH, Park K. Evolutionary chemical binding similarity approach integrated with 3D-QSAR method for effective virtual screening. BMC Bioinformatics 2020;21:309. [PMID: 32664863 DOI: 10.1186/s12859-020-03643-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
302 Xi M, Chen T, Wu C, Gao X, Wu Y, Luo X, Du K, Yu L, Cai T, Shen R, Sun H. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. Eur J Med Chem 2019;164:77-91. [PMID: 30594029 DOI: 10.1016/j.ejmech.2018.11.076] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
303 Zheng S, Tao W. Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs. Front Oncol 2020;10:1517. [PMID: 32983997 DOI: 10.3389/fonc.2020.01517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
304 Tang CC, Castro Andrade CD, O'Meara MJ, Yoon SH, Sato T, Brooks DJ, Bouxsein ML, Martins JDS, Wang J, Gray NS, Misof B, Roschger P, Blouin S, Klaushofer K, Velduis-Vlug A, Vegting Y, Rosen CJ, O'Connell D, Sundberg TB, Xavier RJ, Ung P, Schlessinger A, Kronenberg HM, Berdeaux R, Foretz M, Wein MN. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. Elife 2021;10:e67772. [PMID: 34160349 DOI: 10.7554/eLife.67772] [Reference Citation Analysis]
305 Giannopoulou AF, Velentzas AD, Anagnostopoulos AK, Agalou A, Papandreou NC, Katarachia SA, Koumoundourou DG, Konstantakou EG, Pantazopoulou VI, Delis A, Michailidi MT, Valakos D, Chatzopoulos D, Syntichaki P, Iconomidou VA, Tsitsilonis OE, Papassideri IS, Voutsinas GE, Hatzopoulos P, Thanos D, Beis D, Anastasiadou E, Tsangaris GT, Stravopodis DJ. From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers (Basel) 2021;13:2024. [PMID: 33922182 DOI: 10.3390/cancers13092024] [Reference Citation Analysis]
306 Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem 2022; 13(1): 1-14 [DOI: 10.4331/wjbc.v13.i1.1] [Reference Citation Analysis]
307 Maneiro M, Lence E, Sanz-gaitero M, Otero JM, van Raaij MJ, Thompson P, Hawkins AR, González-bello C. Hydroxylammonium derivatives for selective active-site lysine modification in the anti-virulence bacterial target DHQ1 enzyme. Org Chem Front 2019;6:3127-35. [DOI: 10.1039/c9qo00453j] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
308 Kim SC, Boggu PR, Yu HN, Ki SY, Jung JM, Kim YS, Park GM, Ma SH, Kim IS, Jung YH. Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors. Bioorg Med Chem Lett 2020;30:127189. [PMID: 32371098 DOI: 10.1016/j.bmcl.2020.127189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Olawale F, Iwaloye O, Elekofehinti OO. Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain. J Biomol Struct Dyn 2021;:1-19. [PMID: 34669551 DOI: 10.1080/07391102.2021.1991476] [Reference Citation Analysis]
310 Mabonga L, Kappo AP. Protein-protein interaction modulators: advances, successes and remaining challenges. Biophys Rev 2019;11:559-81. [PMID: 31301019 DOI: 10.1007/s12551-019-00570-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 18.3] [Reference Citation Analysis]
311 Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, Kishton RJ, Vodnala SK, Eidizadeh A, Jia L, Kariya CM, Black MA, Eil R, Palmer DC, Pan JH, Sukumar M, Patel SJ, Restifo NP. Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell 2020;37:818-833.e9. [PMID: 32516591 DOI: 10.1016/j.ccell.2020.05.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
312 Mellinghoff IK, Chang SM, Jaeckle KA, van den Bent M. Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. Hematol Oncol Clin North Am 2022;36:95-111. [PMID: 34711457 DOI: 10.1016/j.hoc.2021.08.008] [Reference Citation Analysis]
313 Bagchee-Clark AJ, Mucaki EJ, Whitehead T, Rogan PK. Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors. MedComm (2020) 2020;1:311-27. [PMID: 34766125 DOI: 10.1002/mco2.46] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
314 Laufkötter O, Hu H, Miljković F, Bajorath J. Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds. J Med Chem 2021. [PMID: 33476146 DOI: 10.1021/acs.jmedchem.0c02076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
315 Nunes PSG, da Silva G, Nascimento S, Mantoani SP, de Andrade P, Bernardes ES, Kawano DF, Leopoldino AM, Carvalho I. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity. Bioorg Chem 2021;113:104982. [PMID: 34020277 DOI: 10.1016/j.bioorg.2021.104982] [Reference Citation Analysis]
316 Jin W. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma. Front Cell Dev Biol 2020;8:613. [PMID: 32754598 DOI: 10.3389/fcell.2020.00613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
317 Hoermann B, Köhn M. Evolutionary crossroads of cell signaling: PP1 and PP2A substrate sites in intrinsically disordered regions. Biochem Soc Trans 2021;49:1065-74. [PMID: 34100859 DOI: 10.1042/BST20200175] [Reference Citation Analysis]
318 De Simone A, Tumiatti V, Andrisano V, Milelli A. Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery? J Med Chem 2021;64:26-41. [PMID: 33346659 DOI: 10.1021/acs.jmedchem.0c00931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
319 Dal corso A, Catalano M, Schmid A, Scheuermann J, Neri D. Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues. Angew Chem 2018;130:17424-8. [DOI: 10.1002/ange.201811650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
320 Raveendra-Panickar D, Finlay D, Layng FI, Lambert LJ, Celeridad M, Zhao M, Barbosa K, De Backer LJS, Kwong E, Gosalia P, Rodiles S, Holleran J, Ardecky R, Grotegut S, Olson S, Hutchinson JH, Pasquale EB, Vuori K, Deshpande AJ, Cosford NDP, Tautz L. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells. J Biol Chem 2021;:101477. [PMID: 34896393 DOI: 10.1016/j.jbc.2021.101477] [Reference Citation Analysis]
321 Toolabi M, Safari F, Ayati A, Fathi P, Moghimi S, Salarinejad S, Foroumadi R, Ketabforoosh SHME, Foroumadi A. Synthesis of novel 2‐acetamide‐5‐phenylthio‐1,3,4‐thiadiazole‐containing phenyl urea derivatives as potential VEGFR‐2 inhibitors. Archiv der Pharmazie. [DOI: 10.1002/ardp.202100397] [Reference Citation Analysis]
322 Lightfoot HL, Goldberg FW, Sedelmeier J. Evolution of Small Molecule Kinase Drugs. ACS Med Chem Lett 2019;10:153-60. [PMID: 30783496 DOI: 10.1021/acsmedchemlett.8b00445] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
323 Bucko PJ, Lombard CK, Rathbun L, Garcia I, Bhat A, Wordeman L, Smith FD, Maly DJ, Hehnly H, Scott JD. Subcellular drug targeting illuminates local kinase action. Elife 2019;8:e52220. [PMID: 31872801 DOI: 10.7554/eLife.52220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
324 Steinebach C, Ng YLD, Sosič I, Lee CS, Chen S, Lindner S, Vu LP, Bricelj A, Haschemi R, Monschke M, Steinwarz E, Wagner KG, Bendas G, Luo J, Gütschow M, Krönke J. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci 2020;11:3474-86. [PMID: 33133483 DOI: 10.1039/d0sc00167h] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
325 Plain F, Howie J, Kennedy J, Brown E, Shattock MJ, Fraser NJ, Fuller W. Control of protein palmitoylation by regulating substrate recruitment to a zDHHC-protein acyltransferase. Commun Biol 2020;3:411. [PMID: 32737405 DOI: 10.1038/s42003-020-01145-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
326 Deznabi I, Arabaci B, Koyutürk M, Tastan O. DeepKinZero: zero-shot learning for predicting kinase-phosphosite associations involving understudied kinases. Bioinformatics 2020;36:3652-61. [PMID: 32044914 DOI: 10.1093/bioinformatics/btaa013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
327 Tovell H, Testa A, Zhou H, Shpiro N, Crafter C, Ciulli A, Alessi DR. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader. ACS Chem Biol 2019;14:2024-34. [PMID: 31461270 DOI: 10.1021/acschembio.9b00505] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
328 Wang H, Qiu J, Liu H, Xu Y, Jia Y, Zhao Y. HKPocket: human kinase pocket database for drug design. BMC Bioinformatics 2019;20:617. [PMID: 31783725 DOI: 10.1186/s12859-019-3254-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
329 Liu X, Long MJC, Hopkins BD, Luo C, Wang L, Aye Y. Precision Targeting of pten-Null Triple-Negative Breast Tumors Guided by Electrophilic Metabolite Sensing. ACS Cent Sci 2020;6:892-902. [PMID: 32607436 DOI: 10.1021/acscentsci.9b00893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
330 Marholz LJ, Federspiel JD, Suh H, Fernandez Ocana M. Highly Multiplexed Kinase Profiling in Spleen with Targeted Mass Spectrometry Reveals Kinome Plasticity across Species. J Proteome Res 2021. [PMID: 34319750 DOI: 10.1021/acs.jproteome.1c00199] [Reference Citation Analysis]
331 Tong M, Yu C, Shi J, Huang W, Ge S, Liu M, Song L, Zhan D, Xia X, Liu W, Feng J, Shi W, Ji J, Gao J, Shi T, Zhu W, Ding C, Wang Y, He F, Shen L, Li T, Qin J. Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer. iScience 2019;22:44-57. [PMID: 31751824 DOI: 10.1016/j.isci.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
332 Robinson-Garcia L, Ferreira da Silva J, Loizou JI. Synthetic Lethal Interactions for Kinase Deficiencies to DNA Damage Chemotherapeutics. Cancer Res 2019;79:5693-8. [PMID: 31387919 DOI: 10.1158/0008-5472.CAN-19-1364] [Reference Citation Analysis]
333 Kaltheuner IH, Anand K, Moecking J, Düster R, Wang J, Gray NS, Geyer M. Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nat Commun 2021;12:6607. [PMID: 34785661 DOI: 10.1038/s41467-021-26935-z] [Reference Citation Analysis]
334 Strauch M, Heyd F. Temperature does matter-an additional dimension in kinase inhibitor development. FEBS J 2021;288:3148-53. [PMID: 32946682 DOI: 10.1111/febs.15564] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Johnson N, Philip N. Beyond phosphorylation: Putative roles of post-translational modifications in Plasmodium sexual stages. Mol Biochem Parasitol 2021;245:111406. [PMID: 34324911 DOI: 10.1016/j.molbiopara.2021.111406] [Reference Citation Analysis]
336 Carapezza G, Cusi C, Rizzo E, Raddrizzani L, Di Bella S, Somaschini A, Leone A, Lupi R, Mutarelli M, Nigro V, di Bernardo D, Magni P, Isacchi A, Bosotti R. Comprehensive kinome NGS targeted expression profiling by KING-REX. BMC Genomics 2019;20:307. [PMID: 31014245 DOI: 10.1186/s12864-019-5676-3] [Reference Citation Analysis]
337 Liu S, Ma H, Zhang H, Deng C, Xin P. Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin Immunol 2021;230:108793. [PMID: 34242749 DOI: 10.1016/j.clim.2021.108793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Asquith C, Tizzard G. 6-Bromo-N-(2-methyl-2H-benzo[d][1,2,3]triazol-5-yl)quinolin-4-amine. Molbank 2019;2019:M1087. [DOI: 10.3390/m1087] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
339 Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021;11:1546-67. [PMID: 33408767 DOI: 10.7150/thno.48662] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
340 Liu R, Yue Z, Tsai CC, Shen J. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors. J Am Chem Soc 2019;141:6553-60. [PMID: 30945531 DOI: 10.1021/jacs.8b13248] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
341 Martín Moyano P, Němec V, Paruch K. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. Int J Mol Sci 2020;21:E7549. [PMID: 33066143 DOI: 10.3390/ijms21207549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
342 Meng N, Zhou S, Hu M, Xu Y, Xia Y, Zeng X, Yu L. Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)-N-methylpicolinamide Derivatives as Potential Antitumor Agents. Molecules 2021;26:1150. [PMID: 33670007 DOI: 10.3390/molecules26041150] [Reference Citation Analysis]
343 Fındık V, Ruiz-López MF, Erdem SS. Mechanistic insights into lysine-targeting covalent inhibition through a theoretical study of ester aminolysis. Org Biomol Chem 2021;19:9996-10004. [PMID: 34755747 DOI: 10.1039/d1ob01963e] [Reference Citation Analysis]
344 Riching KM, Schwinn MK, Vasta JD, Robers MB, Machleidt T, Urh M, Daniels DL. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2. SLAS Discov 2021;26:560-9. [PMID: 33190579 DOI: 10.1177/2472555220973602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
345 Groendyke BJ, Nabet B, Mohardt ML, Zhang H, Peng K, Koide E, Coffey CR, Che J, Scott DA, Bass AJ, Gray NS. Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. ACS Med Chem Lett 2021;12:30-8. [PMID: 33488961 DOI: 10.1021/acsmedchemlett.0c00338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
346 Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep 2021;34:108765. [PMID: 33626345 DOI: 10.1016/j.celrep.2021.108765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Anwar S, Mohammad T, Shamsi A, Queen A, Parveen S, Luqman S, Hasan GM, Alamry KA, Azum N, Asiri AM, Hassan MI. Discovery of Hordenine as a Potential Inhibitor of Pyruvate Dehydrogenase Kinase 3: Implication in Lung Cancer Therapy. Biomedicines 2020;8:E119. [PMID: 32422877 DOI: 10.3390/biomedicines8050119] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
348 Joshi MK, Burton RA, Wu H, Lipchik AM, Craddock BP, Mo H, Parker LL, Miller WT, Post CB. Substrate binding to Src: A new perspective on tyrosine kinase substrate recognition from NMR and molecular dynamics. Protein Sci 2020;29:350-9. [PMID: 31697410 DOI: 10.1002/pro.3777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
349 Simeon S, Jongkon N, Chotpatiwetchkul W, Gleeson MP. Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies. J Comput Aided Mol Des 2019;33:745-57. [PMID: 31494804 DOI: 10.1007/s10822-019-00221-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
350 Correale J. BTK inhibitors as potential therapies for multiple sclerosis. Lancet Neurol 2021;20:689-91. [PMID: 34418385 DOI: 10.1016/S1474-4422(21)00250-7] [Reference Citation Analysis]
351 Houben R, Hesbacher S, Sarma B, Schulte C, Sarosi EM, Popp S, Adam C, Kervarrec T, Schrama D. Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth. Cancer Lett 2022;524:259-67. [PMID: 34715251 DOI: 10.1016/j.canlet.2021.10.031] [Reference Citation Analysis]
352 Albrecht H, Kübler E. Systematic Meta-Analysis Identifies Co-Expressed Kinases and GPCRs in Ovarian Cancer Tissues Revealing a Potential for Targeted Kinase Inhibitor Delivery. Pharmaceutics 2019;11:E454. [PMID: 31480803 DOI: 10.3390/pharmaceutics11090454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
353 He J, Wink S, de Bont H, Le Dévédec S, Zhang Y, van de Water B. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells. Biochemical Pharmacology 2019;169:113640. [DOI: 10.1016/j.bcp.2019.113640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
354 Peerzada MN, Khan P, Khan NS, Avecilla F, Siddiqui SM, Hassan MI, Azam A. Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy. ACS Omega 2020;5:22759-71. [PMID: 32954123 DOI: 10.1021/acsomega.0c01703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
355 Zhang YW, Gallagher K, Angelis D, Rominger D, Scherle P, Vaddi K. Human Plasma In-Cell Western Assays-An In vitro Predictor for In vivo Pharmacology in Oncology Drug Discovery. Curr Protoc 2021;1:e51. [PMID: 33587334 DOI: 10.1002/cpz1.51] [Reference Citation Analysis]
356 Daoud S, Taha MO. Pharmacophore modeling of JAK1: A target infested with activity-cliffs. J Mol Graph Model 2020;99:107615. [PMID: 32339898 DOI: 10.1016/j.jmgm.2020.107615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Ettmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, Michaelides M, Mills CE, Müller S, Owen D, Picado A, Saikatendu KS, Schröder M, Stolz A, Tellechea M, Turunen BJ, Vilar S, Wang J, Zuercher WJ, Willson TM, Drewry DH. The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. Int J Mol Sci 2021;22:E566. [PMID: 33429995 DOI: 10.3390/ijms22020566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
358 Sola AM, Johnson DE, Grandis JR. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opin Investig Drugs 2019;28:351-63. [PMID: 30753792 DOI: 10.1080/13543784.2019.1581172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
359 Deng J, Peng M, Wang Z, Zhou S, Xiao D, Deng J, Yang X, Peng J, Yang X. Novel application of metformin combined with targeted drugs on anticancer treatment. Cancer Sci 2019;110:23-30. [PMID: 30358009 DOI: 10.1111/cas.13849] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
360 Fournier JCL, Evans JP, Zappacosta F, Thomas DA, Patel VK, White GV, Campos S, Tomkinson NCO. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ. ACS Chem Biol 2021. [PMID: 34397208 DOI: 10.1021/acschembio.1c00225] [Reference Citation Analysis]
361 Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT. Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. J Transl Med 2020;18:99. [PMID: 32087721 DOI: 10.1186/s12967-020-02273-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
362 Risha Y, Minic Z, Ghobadloo SM, Berezovski MV. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. Sci Rep 2020;10:13572. [PMID: 32782317 DOI: 10.1038/s41598-020-70393-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
363 Shen C, He Y, Chen Q, Feng H, Williams TM, Lu Y, He Z. Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy. Ann Transl Med 2021;9:1596. [PMID: 34790802 DOI: 10.21037/atm-21-4544] [Reference Citation Analysis]
364 Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hamman BD, Crews CM. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun 2019;10:131. [PMID: 30631068 DOI: 10.1038/s41467-018-08027-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 46.7] [Reference Citation Analysis]
365 Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X, Chen Y. Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies. Front Oncol 2021;11:680834. [PMID: 34123850 DOI: 10.3389/fonc.2021.680834] [Reference Citation Analysis]
366 Favalli EG, Matucci-Cerinic M, Szekanecz Z. The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev 2020;19:102421. [PMID: 31733368 DOI: 10.1016/j.autrev.2019.102421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
367 Sarkar A, Kim EY, Jang T, Hongdusit A, Kim H, Choi JM, Fox JM. Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products. ACS Synth Biol 2021;10:1505-19. [PMID: 33988973 DOI: 10.1021/acssynbio.1c00074] [Reference Citation Analysis]
368 Fagiani F, Lanni C, Racchi M, Govoni S. Targeting dementias through cancer kinases inhibition. Alzheimers Dement (N Y) 2020;6:e12044. [PMID: 32671184 DOI: 10.1002/trc2.12044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
369 van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC, van der Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. Nat Med 2022. [PMID: 35064248 DOI: 10.1038/s41591-021-01643-9] [Reference Citation Analysis]
370 Mayrhofer JE, Enzler F, Feichtner A, Röck R, Fleischmann J, Raffeiner A, Tschaikner P, Ogris E, Huber RG, Hartl M, Schneider R, Troppmair J, Torres-Quesada O, Stefan E. Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. Proc Natl Acad Sci U S A 2020;117:31105-13. [PMID: 33229534 DOI: 10.1073/pnas.2012150117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
371 Toviwek B, Gleeson D, Gleeson MP. QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase. Org Biomol Chem 2021;19:1412-25. [PMID: 33501482 DOI: 10.1039/d0ob02273j] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
372 Liu J, Ma J, Liu Y, Xia J, Li Y, Wang ZP, Wei W. PROTACs: A novel strategy for cancer therapy. Semin Cancer Biol 2020;67:171-9. [PMID: 32058059 DOI: 10.1016/j.semcancer.2020.02.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
373 Wang H, Guan Z, Qiu J, Jia Y, Zeng C, Zhao Y. Novel method to identify group-specific non-catalytic pockets of human kinome for drug design. RSC Adv 2020;10:2004-15. [DOI: 10.1039/c9ra07471f] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19:102523. [PMID: 32205186 DOI: 10.1016/j.autrev.2020.102523] [Cited by in Crossref: 195] [Cited by in F6Publishing: 185] [Article Influence: 97.5] [Reference Citation Analysis]